Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon won 510(k) clearance from the FDA for its next-generation Enseal tissue sealing device with a self-contained power source.

The Enseal G2 cordless device will expand the range of motion in the operating room and can be used in a wide range of surgeries. The device allows for the same sealing "with the added benefits of no set up or interruptions from potential cord tangles," Upstate Medical Center of Syracuse’s Dr. James Kondrup, MD at said on behalf of the company, in prepared remarks.

Sign up to get our free newsletters delivered straight to your inbox

"As healthcare delivery evolves, Ethicon is committed to providing surgeons more choices to meet the unique needs of their patients and procedures, while reducing complexity and helping to reduce cost," said Ethicon CSO Joe Amaral. "We see cordless as one of the advances that delivers on this commitment."

The cordless Enseal device is the 3rd in this product portfolio. The 2nd product in the Enseal line, the Enseal Articulating device, was green-lighted by the federal watchdog agency last month. The FDA also approved the Cincinnati, Ohio-based company’s Biosurgery’s Evarrest surgical patch in December 2012.